PD-L1 and PD-L1 Inhibitors Overview:
Programmed death 1 (PD-1) proteins bind with two ligands, namely Programmed death-ligand 1 (PD-L1) and Programmed death-ligand 2 (PD-L2). Programmed death-ligand 1 (PD-L1) in humans is encoded by the CD274 gene. PD-L1 is also known as cluster of differentiation 274 (CD274).
PD-L1 and PD-L1 Inhibitors Therapies: 200+
PD-L1 and PD-L1 Inhibitors Companies: 180+
Key PD-L1 and PD-L1 Inhibitors Companies
- Merck
- Laekna Therapeutics
- Genentech
- Tracon Pharmaceuticals Inc.
- Celgene
- MedImmune
- Hangzhou Sumgen Biotech
- Lepu Biopharma
- Harbour BioMed
- Curis
- BeiGene
- Apollomics
And several others.
PD-1 AND PD-L1 INHIBITORS Report Assessment
- Company Analysis
- Therapeutic Assessment
- Approved/Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
PD-L1 and PD-L1 Inhibitors Therapeutic Assessment:
- By Product Type
- By Stage and Product Type
- By Route of Administration
- By Stage and Route of Administration
- By Molecule Type
- By Stage and Molecule Type
Related Reports:
PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology And Market Forecast - 2032